Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jan;37(1):106–110. doi: 10.1128/aac.37.1.106

In vitro activities of nucleoside analog antiviral agents against salmonellae.

S J Sperber 1, E L Feibusch 1, A Damiani 1, M P Weinstein 1
PMCID: PMC187613  PMID: 8431005

Abstract

Zidovudine (ZDV) has antibacterial activity against many members of the family Enterobacteriaceae, including Salmonella species, and may be responsible for a decrease in the frequency of salmonellosis in persons infected with human immunodeficiency virus (HIV). Other nucleoside analogs, such as didanosine (2',3'-dideoxyinosine [ddI]) and zalcitabine (2',3'-dideoxycytidine [ddC]), which have undefined anti-salmonella activity, increasingly are being used in the treatment of HIV infection. To evaluate the anti-Salmonella activity of the antiviral agents ZDV, ddI, ddC, and acyclovir (ACV), we determined MICs for 39 nontyphoidal Salmonella blood isolates. ZDV (MIC for 50% of strains tested [MIC50], 0.5 microgram/ml; MIC range, 0.125 to 4 micrograms/ml) and ddI (MIC50, 8 micrograms/ml; MIC range, 2 to 125 micrograms/ml) had concentration-dependent activity. Anti-Salmonella activity was not observed for ddC or ACV. Nine Escherichia coli blood isolates were inhibited by ZDV (MIC50, 0.125 microgram/ml; MIC range, 0.031 to 1 microgram/ml) to a greater degree than they were by ddI (MIC50, 62.5 micrograms/ml; MIC range, 31 to > 62.5 micrograms/ml). Inoculum size affected susceptibility to ZDV and ddI for Salmonella and E. coli isolates. Resistance to ZDV or to ddI could be induced in vitro in Salmonella isolates, but cross-resistance was not observed. These results indicate that at concentrations achieved during the treatment of HIV infection, ZDV has activity against nontyphoidal salmonellae, although resistance can develop. ddI, ddC, and ACV at currently used dosages would not be expected to be effective in the prevention or treatment of Salmonella infections.

Full text

PDF
106

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beskid G., Eskin B., Cleeland R., Siebelist J., Cappetta A., Hill A. D., Geiger R. H. Antibacterial activity of 2',3'-dideoxyadenosine in vivo and in vitro. Antimicrob Agents Chemother. 1981 Mar;19(3):424–428. doi: 10.1128/aac.19.3.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Broder S., Mitsuya H., Yarchoan R., Pavlakis G. N. NIH conference. Antiretroviral therapy in AIDS. Ann Intern Med. 1990 Oct 15;113(8):604–618. doi: 10.7326/0003-4819-113-8-604. [DOI] [PubMed] [Google Scholar]
  3. Cooney D. A., Dalal M., Mitsuya H., McMahon J. B., Nadkarni M., Balzarini J., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol. 1986 Jul 1;35(13):2065–2068. doi: 10.1016/0006-2952(86)90571-x. [DOI] [PubMed] [Google Scholar]
  4. Dahlberg J. E., Mitsuya H., Blam S. B., Broder S., Aaronson S. A. Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2469–2473. doi: 10.1073/pnas.84.8.2469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dellamonica P., Bernard E., Pradier C., Durant J., Etesse-Carsenti H., Elbaze P., Mondain V., Carles M. AZT--does it prevent occurrence of salmonelloses in AIDS patients? J Intern Med. 1991 Jan;229(1):103–103. doi: 10.1111/j.1365-2796.1991.tb00314.x. [DOI] [PubMed] [Google Scholar]
  6. Dolin R., Lambert J. S., Morse G. D., Reichman R. C., Plank C. S., Reid J., Knupp C., McLaren C., Pettinelli C. 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 5):S540–S551. [PubMed] [Google Scholar]
  7. Douglas J. M., Critchlow C., Benedetti J., Mertz G. J., Connor J. D., Hintz M. A., Fahnlander A., Remington M., Winter C., Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984 Jun 14;310(24):1551–1556. doi: 10.1056/NEJM198406143102402. [DOI] [PubMed] [Google Scholar]
  8. Drew R. H., Weller S., Gallis H. A., Walmer K. A., Bartlett J. A., Blum M. R. Bioequivalence assessment of zidovudine (Retrovir) syrup, solution, and capsule formulations in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1989 Oct;33(10):1801–1803. doi: 10.1128/aac.33.10.1801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Elwell L. P., Ferone R., Freeman G. A., Fyfe J. A., Hill J. A., Ray P. H., Richards C. A., Singer S. C., Knick V. B., Rideout J. L. Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U). Antimicrob Agents Chemother. 1987 Feb;31(2):274–280. doi: 10.1128/aac.31.2.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
  11. Herrmann J. L., Lagrange P. H. Intracellular activity of zidovudine (3'-azido-3'-deoxythymidine, AZT) against Salmonella typhimurium in the macrophage cell line J774-2. Antimicrob Agents Chemother. 1992 May;36(5):1081–1085. doi: 10.1128/aac.36.5.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hochster H., Dieterich D., Bozzette S., Reichman R. C., Connor J. D., Liebes L., Sonke R. L., Spector S. A., Valentine F., Pettinelli C. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med. 1990 Jul 15;113(2):111–117. doi: 10.7326/0003-4819-113-2-111. [DOI] [PubMed] [Google Scholar]
  13. Johnson M. A., Fridland A. Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol. 1989 Aug;36(2):291–295. [PubMed] [Google Scholar]
  14. Karlström H. O. Inability of Escherichia coli B to incorporate added deoxycytidine, deoxyandenosine, and deoxyguanosine into DNA. Eur J Biochem. 1970 Nov;17(1):68–71. doi: 10.1111/j.1432-1033.1970.tb01135.x. [DOI] [PubMed] [Google Scholar]
  15. Keith B. R., White G., Wilson H. R. In vivo efficacy of zidovudine (3'-azido-3'-deoxythymidine) in experimental gram-negative-bacterial infections. Antimicrob Agents Chemother. 1989 Apr;33(4):479–483. doi: 10.1128/aac.33.4.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Keller P. M., McKee S. A., Fyfe J. A. Cytoplasmic 5'-nucleotidase catalyzes acyclovir phosphorylation. J Biol Chem. 1985 Jul 25;260(15):8664–8667. [PubMed] [Google Scholar]
  17. Kier L. D., Weppelman R., Ames B. N. Resolution and purification of three periplasmic phosphatases of Salmonella typhimurium. J Bacteriol. 1977 Apr;130(1):399–410. doi: 10.1128/jb.130.1.399-410.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Klecker R. W., Jr, Collins J. M., Yarchoan R. C., Thomas R., McAtee N., Broder S., Myers C. E. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol. 1988 Sep;28(9):837–842. doi: 10.1002/j.1552-4604.1988.tb03225.x. [DOI] [PubMed] [Google Scholar]
  19. Lewin C. S., Allen R. A., Amyes S. G. Mechanisms of zidovudine resistance in bacteria. J Med Microbiol. 1990 Dec;33(4):235–238. doi: 10.1099/00222615-33-4-235. [DOI] [PubMed] [Google Scholar]
  20. Lewin C. S., Allen R., Amyes S. G. Zidovudine-resistance in Salmonella typhimurium and Escherichia coli. J Antimicrob Chemother. 1990 Apr;25(4):706–708. doi: 10.1093/jac/25.4.706. [DOI] [PubMed] [Google Scholar]
  21. Lewin C. S., Amyes S. G. Conditions required for the antibacterial activity of zidovudine. Eur J Clin Microbiol Infect Dis. 1989 Aug;8(8):737–741. doi: 10.1007/BF01963765. [DOI] [PubMed] [Google Scholar]
  22. Lewin C. S., Watt B., Paton R., Amyes S. G. Isolation of zidovudine resistant Escherichia coli from AIDS patients. FEMS Microbiol Lett. 1990 Jul;58(2):141–143. doi: 10.1111/j.1574-6968.1990.tb13967.x. [DOI] [PubMed] [Google Scholar]
  23. Neu H. C., Chou J. Release of surface enzymes in Enterobacteriaceae by osmotic shock. J Bacteriol. 1967 Dec;94(6):1934–1945. doi: 10.1128/jb.94.6.1934-1945.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Neu H. C. The 5'-nucleotidase of Escherichia coli. I. Purification and properties. J Biol Chem. 1967 Sep 10;242(17):3896–3904. [PubMed] [Google Scholar]
  25. Neuhard J. Pyrimidine nucleotide metabolism and pathways of thymidine triphosphate biosynthesis in Salmonella typhimurium. J Bacteriol. 1968 Nov;96(5):1519–1527. doi: 10.1128/jb.96.5.1519-1527.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Saito H., Tomioka H., Ohkido S. Further studies on thymidine kinase: distribution pattern of the enzyme in bacteria. J Gen Microbiol. 1985 Nov;131(11):3091–3098. doi: 10.1099/00221287-131-11-3091. [DOI] [PubMed] [Google Scholar]
  27. Salmon D., Detruchis P., Leport C., Bouvet E., Karam D., Meyohas M. C., Coulaud J. P., Vildé J. L. Efficacy of zidovudine in preventing relapses of Salmonella bacteremia in AIDS. J Infect Dis. 1991 Feb;163(2):415–416. doi: 10.1093/infdis/163.2.415. [DOI] [PubMed] [Google Scholar]
  28. Sperber S. J., Schleupner C. J. Salmonellosis during infection with human immunodeficiency virus. Rev Infect Dis. 1987 Sep-Oct;9(5):925–934. doi: 10.1093/clinids/9.5.925. [DOI] [PubMed] [Google Scholar]
  29. Surbone A., Yarchoan R., McAtee N., Blum M. R., Maha M., Allain J. P., Thomas R. V., Mitsuya H., Lehrman S. N., Leuther M. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study. Ann Intern Med. 1988 Apr;108(4):534–540. doi: 10.7326/0003-4819-108-4-534. [DOI] [PubMed] [Google Scholar]
  30. Tilton R. C., Lieberman L., Gerlach E. H. Microdilution antibiotic susceptibility test: examination of certain variables. Appl Microbiol. 1973 Nov;26(5):658–665. doi: 10.1128/am.26.5.658-665.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989 Sep 14;321(11):726–738. doi: 10.1056/NEJM198909143211106. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES